Abstract
Oncogenic Ras proteins have been seen as an important target for novel anticancer drugs. Due to the functional role of Ras farnesylation, fanesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. Although it has been clearly demonstrated that FTase inhibitors (FTIs) inhibit Ras farnesylation, it is uncertain whether the antiproliferative effects of these compounds result exclusively from the effects on Ras. Moreover, no consensus has been reached as to the relevant targets(s) of FTIs that can explain their mosaic pharmacology. In searching for downstream targets for FTIs effects, CENP-E and CENP-F / mitosin were identified. Different studies showed that the inhibition of farnesylation interferes with CENP-E-microtubule association. In the presence of FTIs, chromosome alignment to the metaphase plate is delayed, suggesting that farnesylated proteins are involved in a step critical to bipolar spindle formation and chromosome alignment. An important question is whether these biological effects might contribute to the chemotherapeutic effects of the FTIs. However, FTIs, triggering the spindle checkpoint, might elevate the rate of cellular missegregation to levels that are incompatible with cell viability, as well as have a reduced (but still significant?) effect on checkpointproficient normal cells. As an example, RPR-115135 induced micronuclei (MN) increase in cancer cells displaying high chromosome instability (CIN) levels, whereas in normal cells it is devoid of activity. Cancer cells showing high CIN level might represent an ideal target for the activity of some FTIs.
Keywords: Increasing Complexity, Farnesyltransferase Inhibitors, Chromosome Instability, Oncogenic, fanesyltransferase (FTase)
Current Cancer Drug Targets
Title: Increasing Complexity of Farnesyltransferase Inhibitors Activity: Role in Chromosome Instability
Volume: 3 Issue: 2
Author(s): Carla Falugi, Sonya Trombino, Pierluigi Granone, Stefano Margaritora and Patrizia Russo
Affiliation:
Keywords: Increasing Complexity, Farnesyltransferase Inhibitors, Chromosome Instability, Oncogenic, fanesyltransferase (FTase)
Abstract: Oncogenic Ras proteins have been seen as an important target for novel anticancer drugs. Due to the functional role of Ras farnesylation, fanesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. Although it has been clearly demonstrated that FTase inhibitors (FTIs) inhibit Ras farnesylation, it is uncertain whether the antiproliferative effects of these compounds result exclusively from the effects on Ras. Moreover, no consensus has been reached as to the relevant targets(s) of FTIs that can explain their mosaic pharmacology. In searching for downstream targets for FTIs effects, CENP-E and CENP-F / mitosin were identified. Different studies showed that the inhibition of farnesylation interferes with CENP-E-microtubule association. In the presence of FTIs, chromosome alignment to the metaphase plate is delayed, suggesting that farnesylated proteins are involved in a step critical to bipolar spindle formation and chromosome alignment. An important question is whether these biological effects might contribute to the chemotherapeutic effects of the FTIs. However, FTIs, triggering the spindle checkpoint, might elevate the rate of cellular missegregation to levels that are incompatible with cell viability, as well as have a reduced (but still significant?) effect on checkpointproficient normal cells. As an example, RPR-115135 induced micronuclei (MN) increase in cancer cells displaying high chromosome instability (CIN) levels, whereas in normal cells it is devoid of activity. Cancer cells showing high CIN level might represent an ideal target for the activity of some FTIs.
Export Options
About this article
Cite this article as:
Falugi Carla, Trombino Sonya, Granone Pierluigi, Margaritora Stefano and Russo Patrizia, Increasing Complexity of Farnesyltransferase Inhibitors Activity: Role in Chromosome Instability, Current Cancer Drug Targets 2003; 3 (2) . https://dx.doi.org/10.2174/1568009033482056
DOI https://dx.doi.org/10.2174/1568009033482056 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment
Current Pharmaceutical Design Meet the Editorial Board
Current Medicinal Chemistry Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews Prophylactic Potential of Conventional and Supercritical Garlic Extracts to Alleviate Diet Related Malfunctions
Recent Patents on Food, Nutrition & Agriculture Potential Future of New Glutamate Agonists and Antagonists Development
Anti-Cancer Agents in Medicinal Chemistry Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Letters in Drug Design & Discovery STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry A Preliminary Assessment of the Structure-Activity Relationship of Benzimidazole-Based Anti-Proliferative Agents
Letters in Drug Design & Discovery Experimental Models for Evaluation of Nanoparticles in Cancer Therapy
Mini-Reviews in Medicinal Chemistry The Application of the Cold Atmospheric Plasma-Activated Solutions in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology Assessing Combinations of Cytotoxic Agents Using Leukemia Cell Lines
Current Drug Targets The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology Overview of Dietary Influences on Atherosclerotic Vascular Disease:Epidemiology and Prevention
Cardiovascular & Hematological Disorders-Drug Targets The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Current Topics in Medicinal Chemistry A Practical Guide to Molecular Docking and Homology Modelling for Medicinal Chemists
Current Topics in Medicinal Chemistry Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery